Eyebright Medical Technology (Beijing)'s (SHSE:688050) Solid Earnings May Rest On Weak Foundations
Following the solid earnings report from Eyebright Medical Technology (Beijing) Co., Ltd. (SHSE:688050), the market responded by bidding up the stock price. While the profit numbers were good, our an
Aibo Healthcare (688050): Revenue has greatly accelerated and the contribution ratio of the contact lens sector has increased
The company's 2023 operating income was 950 million yuan (up 64.14% year on year), net profit due to mother was 304 million yuan (up 30.63% year on year), net profit after deducting non-return to mother was 289 million yuan (year-on-year increase of 38.9 million yuan)
Southwest Securities released a research report on April 22 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) the 2023 performance was in line with expectations, and the 2024Q1 performance was
Southwest Securities released a research report on April 22 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) the 2023 performance was in line with expectations, and the 2024Q1 performance was outstanding; 2) R&D investment increased and sales expenses increased; 3) the expansion of the contact lens business segment to continuously improve production line efficiency. (Mainichi Keizai Shimbun)
Guohai Securities released a research report on April 21 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) the surgical treatment and myopia prevention and control business continues to grow, a
Guohai Securities released a research report on April 21 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) the surgical treatment and myopia prevention and control business continues to grow, and the vision care business is expanding rapidly; 2) the rich research pipeline gives the company continued high growth. (Mainichi Keizai Shimbun)
Aibo Healthcare (688050): Performance exceeds expectations, rapid expansion of contact lens business
Incident: The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved revenue of 951 million yuan (+64% year over year, same below), net profit attributable to mother of 304 million yuan (+31%), net profit not attributable to mother
Aibo Healthcare (688050): Maintaining High Growth and Further Enriching Research Projects
Incident: Aibo Healthcare released its 2023 annual report and 2024 quarterly report on April 17: In 2023, the company achieved revenue of 951 million yuan (+64%, year-on-year scale, same below) and net profit of 3.04 million yuan to mother
Dongwu Securities released a research report on April 19 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) gross margin declined slightly due to changes in revenue structure; 2) the second grow
Dongwu Securities released a research report on April 19 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) gross margin declined slightly due to changes in revenue structure; 2) the second growth curve for the contact lens business opened; 3) Continued increase in R&D investment, and the clinical progress of new products is good. (Mainichi Keizai Shimbun)
Aibo Healthcare (688050): Performance exceeds expectations, contact lenses became the second growth curve
Introduction to this report: The company's 2024Q1 performance exceeded expectations. It is expected that the performance will grow steadily in the future, mainly due to the rapid increase in contact lenses and the release of profits due to the expansion of production lines and scale advantages. Key investment points: Maintain a prudent holdings increase rating. Khao
Aibo Healthcare (688050): Performance maintains rapid growth and rapid release of optometry products
Key investment results maintained rapid growth: the company released the 2023 annual report and the 2024 quarterly report, and achieved operating income of 951 million yuan in 2023 (+64%, year-on-year growth rate, same as below) and net profit of 3.04 million yuan to mother
Aibo Healthcare (688050) 23rd Annual Report and 24Q1 Quarterly Report Review: Revenue and Profit Increased in the First Quarterly Report; Contact Lens Business Expands Hyaluronic Acid into Clinical Practice
The annual report results are consistent with the express report: 1) In '23, the company achieved revenue of 951 million yuan/year on year +64.14%, with a return of 304 million yuan/year over year +30.63%, after deducting not 289 million yuan/year on year +38.96%
Cinda Securities released a research report on April 18 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) the annual report's performance is consistent with the quick report; 2) the quarterly r
Cinda Securities released a research report on April 18 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) the annual report's performance is consistent with the quick report; 2) the quarterly report's revenue and profit increased; 3) the surgical business was booming domestically and rapidly expanded overseas in '23, and the national procurement is about to be implemented; 4) the contact lens business is the leader in the industry and has become the company's third growth curve; 5) continuous investment in R&D, and various key products are worth looking forward to. (Mainichi Keizai Shimbun)
Aibo Healthcare (688050): Mining implementation accelerates volume acquisitions to help business layout
Performance Overview On April 17, 2024, the company released its 2023 annual report. In 2023, the company achieved revenue of 951 million yuan (+64% year over year); realized net profit of 304 million yuan (+3 year over year)
Aibo Healthcare (688050): Steady development of artificial crystals and rapid release of new products
Incident: In 2023, Aibo Healthcare achieved revenue of 951 million yuan, an increase of 64.14% over the previous year; realized net profit of 304 million yuan, an increase of 30.63% over the previous year. 2024Q1 Aibo Healthcare achieved revenue 3.1
Aibo Healthcare (688050) 2023 and 2024Q1 performance review: Performance exceeds expectations, contact lenses became the second growth curve
Introduction to this report: The company's 2024Q1 performance exceeded expectations. It is expected that the performance will grow steadily in the future, mainly due to the rapid increase in contact lenses and the release of profits due to the expansion of production lines and scale advantages. Key investment points: Maintain a prudent holdings increase rating. contemplates
Aibo Healthcare (688050): Crystal Procurement helps steadily increase sales volume, and rapid release of soft lenses can be expected, profits can be expected
Incident: On the evening of April 17, 2024, Aibo Healthcare released its 2023 report and 24Q1 report; in 2023, the company achieved revenue of 950 million yuan (+64.14%) and net profit of 304 million yuan (+30)
Express News | Aibo Healthcare: Net profit of 303 million yuan in 2023 increased by 30.63% year-on-year, and plans to increase 10 to 8 percent by 4.9 yuan
Eyebright Medical Technology (Beijing) (SHSE:688050) Is Looking To Continue Growing Its Returns On Capital
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a business will show two trends; firstly a growing return on capital employed (ROC
Aibo Healthcare (688050.SH): Product passed a special review process for innovative medical devices
Gelonghui, April 2 | Aibo Medical (688050.SH) announced that the company's “artificial lens” recently passed the Special Examination Procedure for Innovative Medical Devices by the Medical Device Technology Review Center of the State Drug Administration (Innovation Review Acceptance Number: CQTS2400048). This product is an artificial lens with the effect of extending depth of field. While providing farsightedness comparable to that of ordinary single-focus intraocular lenses, patients can benefit from useful medium- and near-vision. Currently, all domestic depth-of-field intraocular lens products rely on imports. The extended depth of field intraocular lens products developed by the company is based on many innovations
Aibo Healthcare (688050.SH): A total cost of 2004 million yuan to buy back 0.14% of shares
Gelonghui, April 1 | Aibo Healthcare (688050.SH) announced that as of March 31, 2024, the company had repurchased 142,800 shares of the company's shares through centralized bidding transactions, accounting for 0.14% of the company's total share capital of 105,250,992 shares. The highest price of the repurchase transaction was 147.90 yuan/share, the lowest price was 134.10 yuan/share, and the total amount of capital paid was RMB 20,043,605.54 (excluding transaction fees such as stamp duty and transaction fees).
Express News | Aibo Healthcare: Multifocal intraocular lenses entered the national public hospital system for the first time, enjoying a 20% premium
No Data